Clinical Trial

NWRD06 DNA Plasmid for HCC After Curative Resection.

Name: NWRD06 DNA Plasmid for HCC After Curative Resection. — clinical trial record (NCT07324304)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.

Trial Details

NCT Number	NCT07324304
Lead Sponsor	Newish Technology (Beijing) Co., Ltd.
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	30 participants
Start Date	2025-12-08
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-07